AEON Biopharma, Inc. (AEON) Company Total Revenue

AEON Biopharma is developing a botulinum toxin platform to combat migraines, mitigating risks through the aesthetics segment. On GURU.Markets, the company's current performance metrics reflect an industry trend where the 0.00 mark serves as a relevant indicator. The chronic profile of these pathologies ensures stable demand for the drugs. A focus on medicine allows the brand to avoid dumping, maintaining high competitiveness within the field of neurology.

AEON - AEON Biopharma Inc. Company Revenue over the range 02/21/2024 - 11/15/2026

Analytical breakdowns for AEON Biopharma Inc. (AEON)

- share price and expert price forecast:

Price Performance Chart aeonbiopharma.com|AEON - Price Target Chart

- market capitalization details:

Market Value AEON Bio|AEON - Total Company Value

- book value of equity indicators:

Net Assets per Single Share AEON Biopharma|AEON - Company Book Value|Market-to-Book Ratio aeonbiopharma.com|AEON - Company Total Assets

- company liabilities and liquidity data:

- earnings and market ratios statistics:

AEON - Company Net Income|Net Profit Forecast AEON Biopharma|AEON - Price to Earnings Ratio|Future Price to Earnings Multiple AEON Biopharma|AEON - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization AEON Biopharma Inc.|AEON - Operating profit EBITDA|Net earnings per share for the last four quarters AEON Biopharma|AEON - Earnings per share for the last twelve months|Earnings per share growth in annualized terms for the last twelve months aeonbiopharma.com|AEON - Earnings per share growth in current year|Net earnings per share change forecast for next year AEON Biopharma

- sales volume and revenue indicators:

AEON - Revenue and Sales Volume|Company Future Revenue AEON Biopharma|AEON - P/S Multiple|Forward P/S Multiple AEON Bio

Summary company analysis:AEON, AEON Biopharma, Inc.

Mass-produced product of AEON Biopharma, Inc.

Exclusive patents for ABP-450 and stringent FDA oversight dictate the commercialization pace of AEON Biopharma drugs, directly impacting cash flow. The daily volume of inflows, reflected in the company's commercial sales figures, measures real market demand and product liquidity, allowing investors to assess the actual capitalization of the business and avoid asset overvaluation risks.

Key competitors